Abstract
Unfortunately, antiepileptic drug therapy fails to control seizure activity in a relevant percentage of epilepsy patients. Epidemiological data as well as findings in human epileptic tissue and in rodent models indicate that drug resistance is a multi-factorial phenomenon with various factors contributing to therapeutic failure. Enhanced efflux transport of antiepileptic drugs as a consequence of seizure-associated up-regulation of transporters such as P-glycoprotein constitutes one factor discussed in this context. Evidence exists that expression rates of P-glycoprotein correlate with drug response in rodent models and in patients. Moreover, add-on of a Pglycoprotein modulator proved to be efficacious in a rat model of drug-resistant epilepsy.
Further proof is obviously needed regarding the relative functional relevance of blood-brain barrier efflux for antiepileptic drug efficacy in epilepsy patients. Ongoing studies with positron emission tomography using transporter substrate radiotracers might provide further information. However, these studies also face major challenges considering the complexity of various factors affecting the kinetics of radiotracers in central nervous system pathologies.
Keywords: Seizure, blood-brain barrier, transporter, drug resistance, p-glycoprotein.
Current Pharmaceutical Design
Title:CNS Transporters and Drug Delivery in Epilepsy
Volume: 20 Issue: 10
Author(s): Heidrun Potschka and Hiram Luna-Munguia
Affiliation:
Keywords: Seizure, blood-brain barrier, transporter, drug resistance, p-glycoprotein.
Abstract: Unfortunately, antiepileptic drug therapy fails to control seizure activity in a relevant percentage of epilepsy patients. Epidemiological data as well as findings in human epileptic tissue and in rodent models indicate that drug resistance is a multi-factorial phenomenon with various factors contributing to therapeutic failure. Enhanced efflux transport of antiepileptic drugs as a consequence of seizure-associated up-regulation of transporters such as P-glycoprotein constitutes one factor discussed in this context. Evidence exists that expression rates of P-glycoprotein correlate with drug response in rodent models and in patients. Moreover, add-on of a Pglycoprotein modulator proved to be efficacious in a rat model of drug-resistant epilepsy.
Further proof is obviously needed regarding the relative functional relevance of blood-brain barrier efflux for antiepileptic drug efficacy in epilepsy patients. Ongoing studies with positron emission tomography using transporter substrate radiotracers might provide further information. However, these studies also face major challenges considering the complexity of various factors affecting the kinetics of radiotracers in central nervous system pathologies.
Export Options
About this article
Cite this article as:
Potschka Heidrun and Luna-Munguia Hiram, CNS Transporters and Drug Delivery in Epilepsy, Current Pharmaceutical Design 2014; 20 (10) . https://dx.doi.org/10.2174/13816128113199990461
DOI https://dx.doi.org/10.2174/13816128113199990461 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Teratogenic Potential of Atypical Antipsychotic Drugs, Quetiapine and Aripiprazole in Rats
Current Psychopharmacology Editorial: Antiepileptic Drugs in Neurosurgical Practic
Current Pharmaceutical Design A Review on GABA/Glutamate Pathway for Therapeutic Intervention of ASD and ADHD
Current Medicinal Chemistry Current Development in Encapsulated Cell Therapy for Degenerative Retinopathies
Current Tissue Engineering (Discontinued) Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry GABAB Receptors as Potential Therapeutic Targets
Current Drug Targets - CNS & Neurological Disorders Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology Voltage-Gated Sodium Channels and Pain
Current Drug Targets - CNS & Neurological Disorders N-Valproyl-L-Tryptophan for CNS-Targeting: Synthesis, Characterization and Efficacy In Vitro Studies of a New Potential Antiepileptic Drug
Medicinal Chemistry Repetitive Transcranial Magnetic Stimulation (rTMS) to Treat Refractory Panic Disorder Patient: A Case Report
CNS & Neurological Disorders - Drug Targets 5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
CNS & Neurological Disorders - Drug Targets Metabolic Syndrome and Psychiatric Practice: Clinical and Management Issues
Current Psychiatry Reviews Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Current Pharmaceutical Design Psychoemotional Background of Temporomandibular Joint Dysfunction and Possible Drug Therapy
Letters in Drug Design & Discovery Sexual Dysfunction in Epilepsy and the Role of Anti-Epileptic Drugs
Current Pharmaceutical Design Role of the Endocannabinoid System in the Neuroendocrine Responses to Inflammation
Current Pharmaceutical Design Novel Methods of Genetic Modification of Human Pluripotent Stem Cells
Recent Patents on Regenerative Medicine Physiological Roles of Neuronal Nicotinic Receptors Subtypes: New Insights on the Nicotinic Modulation of Neurotransmitter Release, Synaptic Transmission and Plasticity
Current Topics in Medicinal Chemistry Mitochondrial Dysfunction and Its Relationship with mTOR Signaling and Oxidative Damage in Autism Spectrum Disorders
Mini-Reviews in Medicinal Chemistry